Tradestie Institutional Equity Comparison Engine

MRNA vs SYRE โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MRNA Overall Edge

MRNA Captures Institutional Edge (3โ€“1 Pillars ยท 6โ€“4 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Moderna, Inc. Common Stock (MRNA) driven by superior Valuation, Momentum & Technical, Options & Structure while SYRE counters with relative strength in Growth & Margin. Fundamentally, MRNA trades at 23.0x Forward P/E with -80.8% operating margin (+29.2% YoY revenue) versus SYRE at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, MRNA sits in CONSOLIDATION (30th %ile IV; Dealer Gamma Walls on Pro) against SYRE sits in UNCLASSIFIED (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner MRNA
MRNA 23.0x vs SYRE N/M Fwd P/E
Growth & Margin Winner SYRE
Op Margin -80.8% vs 0.0% ยท YoY +29.2% vs +0.0%
Momentum & Technical Winner MRNA
1Y +765.2% vs +341.7% ยท 52W Pos 75% vs 88%
Options & Structure Winner MRNA
CONSOLIDATION (30th %ile IV) vs UNCLASSIFIED (10th %ile IV)
MRNA NASDAQ
Moderna, Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$215.96
-3.32% 1D
Market Cap $93.6B
1M Return -0.94%
1Y Return +765.2%
Forward P/E 23.0x
Unified AI Score
46.8 / 100 HOLD
Tech 41.0 Fund 50.0 Flow 67.0 Mom 41.1
SYRE NASDAQ
Spyre Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$99.97
-3.88% 1D
Market Cap $9.8B
1M Return +25.11%
1Y Return +341.74%
Forward P/E N/M
Unified AI Score
44.4 / 100 HOLD
Tech 31.0 Fund 33.0 Flow 50.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: MRNA +765.2% SYRE +341.74% Spread: +423.46 pp (MRNA Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
MRNA TTM Op. Margin: -80.8% SYRE TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on MRNA vs SYRE. Trailing 12-month operating profitability (MRNA -80.8% vs SYRE 0.0%) and valuation multiples (MRNA 23.0x vs SYRE N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: MRNA (6) vs SYRE (4)
Institutional Metric MRNA SYRE Criterion Row Winner
Market Capitalization Scale $93.6B $9.8B Larger Scale MRNA
Trailing P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Forward P/E Ratio Valuation 23.0x N/M Lower Multiple MRNA
Revenue Growth (YoY) Growth +29.2% +0.0% Higher Growth MRNA
Operating Margin (TTM) Profitability -80.8% 0.0% Higher Margin SYRE
Net Profit Margin Profitability -110.5% 0.0% Higher Margin SYRE
Return on Equity (ROE) Capital Efficiency -34.5% -35.0% Higher ROE MRNA
52-Week Range Position Momentum 75% ($22โ€“$281) 88% ($22โ€“$111) Stronger Trend SYRE
Beta / 30D Volatility Risk Regime 2.35ฮฒ ยท 101% Vol 1.75ฮฒ ยท 59% Vol Lower Realized Risk SYRE
Unified Institutional Score Composite Signal 46.8 / 100 (HOLD) 44.4 / 100 (HOLD) Higher Composite MRNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full MRNA vs SYRE Buy Guide
MRNA CONSOLIDATION
18d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 30th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live MRNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
SYRE UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live SYRE Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither MRNA nor SYRE registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.